Clinical Trials Logo

REM Behavior Disorder clinical trials

View clinical trials related to REM Behavior Disorder.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05922995 Not yet recruiting - Clinical trials for REM Behavior Disorder

The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

RBD
Start date: September 30, 2023
Phase: Early Phase 1
Study type: Interventional

To assess the effects of a daily single oral dose of 20 mg tasimelteon compared to baseline on events of dream enactment on patients with REM Behavior Disorder, as measured by a daily log. To assess the effects of 20 mg tasimelteon compared to baseline on insomnia= symptoms, as measured by validated questionnaires (Insomnia Severity Index [ISI], Pittsburgh Sleep Quality Inventory [PSQI], Epworth Sleepiness Scale [ESS], Clinical Global Impression of Change Scale (CGI-C), Patient Global Impression of Change Scale (PGI-C)) as well as rest/activity pattern from actigraphy. - To assess the effects of 20 mg tasimelteon on patients who have a reduced or aberrant melatonin secretion compared to normal secretion by measuring salivary DLMO at baseline and correlating with the degree of change in RBD symptoms by end of the study. - To assess for any role a patient's unique genome may play in their response to tasimelteon; obtained via whole genome sequencing. - To assess the safety and tolerability of a daily single oral dose of 20 mg tasimelteon.